Obefazimod in Patients With Moderate-to-Severe Ulcerative Colitis: Efficacy and Safety Analysis From the 96-Week Open-Label Maintenance Phase 2b Study

The requested reference [13cb904dc562a5dfb008e961f85b96bfe9ae805a] no longer exists in our database. It has been replaced by the current reference: [c67c4d86e023960b324671a7c74a9a936bb57ef4]

Authors
Category Primary study
ConferenceAmerican College of Gastroenterology Annual Meeting, ACG 2023
Year 2023
This article has no abstract
Epistemonikos ID: fb2d294246e817da59c1e41094bc244b774700b3
First added on: Apr 19, 2025